Purpose: Small cell lung cancer (SCLC) historically has had poor prognosis. Clinical trials have demonstrated improved survival among patients receiving standard platinum-/etoposide-based chemotherapy. Whereas treatment patterns and outcomes have been evaluated for patients with SCLC in clinical trials, population-based practice patterns are not well known.
S mall cell lung cancer (SCLC) is the fifth leading cause of cancer mortality in the United States and accounts for approximately 15% of the more than 200,000 lung cancers diagnosed each year. 1, 2 Patients with a diagnosis of SCLC have a very poor prognosis, with median survival of 16 to 24 months for limitedstage (LS) disease and 10 to 12 months for extensive-stage (ES) disease. 3, 4 Compared with other types of lung cancer, most patients with SCLC present with widely disseminated disease at diagnosis. 4 Although chemotherapy and radiation can favorably affect the natural course of the disease, overall improvements in outcomes for SCLC over the past 25 years have been limited. [3] [4] [5] In fact, the inclusion of prophylactic cranial irradiation (PCI) for patients with both LS and ES diseases with very good response to initial therapy could be considered the most recent significant advance in the management of this disease. 6, 7 Phase 3 clinical trials have demonstrated improved survival in patients treated with a combination of etoposide with cisplatinum or carboplatin. 5 Current practice guidelines recommend that patients presenting with LS disease receive a combination of chemotherapy and radiation, whereas those with ES disease receive chemotherapy only. 5, 8, 9 Patients with ES who have a very good response to initial systemic treatment may be offered additional thoracic radiation to the primary mass to further improve disease control or to sites of metastatic disease for palliation purposes. 5, 10 However, there is no definitive evidence of added survival benefit with this approach, and, for the purpose of this analysis, we will consider chemotherapy only as the standard approach for treatment of ES. No consistent benefit of alternative regimens has been demonstrated over this standard. [10] [11] [12] [13] [14] [15] [16] Improvements in the survival of patients with SCLC have been achieved through well-designed clinical trials that build on the best available therapies, 11, 12 so patient entry for such trials is highly desirable. Treatments and outcomes for patients with SCLC have been evaluated in the clinical trial and comprehensive cancer center setting, 17 but population-based practice patterns in the US community and academic settings are not well described.
The purposes of our study were to evaluate patterns of treatment for patients with newly diagnosed SCLC in the US community and academic settings and to evaluate the use of chemotherapy combinations, thoracic radiation, and clinical trial participation on outcomes. Using the National Cancer Institute's Patterns of Care Study, we present a populationbased analysis of patient, provider, and tumor characteristics associated with receipt of recommended therapy by stage at diagnosis for SCLC. We evaluated these factors for associations with 12-month relative hazard of death. on incident cancer diagnoses and survival for approximately 28% of the US population. 18 The SEER program routinely collects information on cancer stage, initial therapy, patients'demographics, and follow-up for vital status. However, because SEER data collection is primarily hospital based, therapy administered in an outpatient setting can be underreported. To obtain more complete treatment information, the annual National Cancer Institute's Patterns of Care (POC) study reviews medical records and queries physicians to obtain information on cancer therapies for selected cancers. 19 Surveillance, Epidemiology and End Results-registered patients with SCLC were stratified by age, race/ethnicity, and registry; and a random sample was selected from each stratum for the Patterns of Care study. Non-Hispanic blacks, Hispanics, Asian/Pacific Islanders, and American Indians/Alaskan Natives were oversampled to obtain more stable estimates. Institutional review board approval was received as required by the registries. Each patient's doctor was contacted to verify specific treatments administered, including agents and dates of initial therapy and provide the name(s) of other physicians who might have treated the patient, and these additional physicians were also contacted. Hospital medical records were reviewed to identify patients' comorbidities, confirm tumor characteristics and treatments. Treatment was verified by physician report or hospital records in 98.8% of the patients. Finally, information about hospital characteristics was recorded.
Patients
We included patients with histologically confirmed SCLC diagnosis or mixed histologic classifications. Patients with lung sarcoma were ineligible. Patients were also ineligible if they had a history of cancer (other than nonmelanoma skin cancer); had a simultaneous diagnosis of a second primary cancer; or had a diagnosis at autopsy or on death certificates only. Patients undergoing surgical resection (n=27) as a component of their initial treatment were excluded as information regarding what led to the choice of surgery (i.e., suspected non-small cell histology) was unavailable in our study and would make medical interpretation of our results difficult. 20, 21 After exclusions, our final sample included 931 patients with SCLC.
Staging and Therapy
Patients were grouped according to the standard classification of LS or ES disease at presentation according to physician's report or hospital record verification of the stage at diagnosis. 5 We evaluated initial therapeutic treatment received and 12-month mortality for patients with newly diagnosed SCLC. Initial therapy was defined as treatment that was administered or planned before progression or recurrence of the disease, as verified by the physician. Treatment for SCLC was classified as follows: chemotherapy alone, thoracic radiation therapy alone to the primary site, chemotherapy plus thoracic radiation, and no/ unknown treatment. Chemotherapy regimens were further classified as etoposide with cisplatin or carboplatin or "other" chemotherapy. We considered US standard chemotherapy the receipt of the doublet etoposide plus either cisplatin or carboplatin. Patients receiving other chemotherapy within 2 months of diagnosis, even if administered in addition to the standard doublet, were categorized as other chemotherapy because a 3-drug regimen was not considered standard of care. Although the combination of platinum plus irinotecan is considered by some as an acceptable initial standard treatment, the confirmatory phase 3 study in the US population (SWOG S0124) did not confirm the superiority of that doublet against the US standard of cisplatin/etoposide, 22 as seen in the Japanese studies. Activity was similar with both treatment combinations, but irinotecan led to a worse toxicity profile for the US population. The conclusion arising from SWOG S0124 was that platinum/etoposide remains the reference treatment standard for the US population. Therefore, for the purpose of this analysis, we considered the platinum/etoposide combination the standard regimen for ES SCLC.
The codes for radiation site were to the (1) primary site (i.e., thoracic) and/or (2) to an unspecified nonprimary site at the time of initial treatment. Radiation to the nonprimary site was before progression or recurrence; not for palliative therapy. We used these data to investigate the administration of central nervous system (CNS) radiation for patients with LS disease. By definition, patients with LS disease do not have metastatic disease; therefore, although the coding does not specifically refer to radiation to a CNS site, radiation to a nonprimary site was attributed to CNS radiation (e.g., PCI). Because by LS definition, there were no metastatic sites, it is highly unlikely that this radiation would have been given to any nonprimary site other than the brain. Therefore, even with the noted limitation, it is reasonable to infer that radiation was delivered to the brain as PCI. Time to death for 12-month mortality calculations was defined as the time, in months, from a patient's diagnosis until death.
Analysis
We used χ 2 analyses to assess the unadjusted association between the patient, the provider, and treatment characteristics and stage at diagnosis. Logistic regression evaluated the association between patient characteristics, provider characteristics, and treatment for SCLC. Models were stratified by extent of disease at presentation. For patients with LS, we evaluated factors associated with (1) etoposide with cisplatin or carboplatin and thoracic radiation and (2) any chemotherapy with thoracic radiation. For patients with ES, we evaluated factors associated with (1) etoposide with cisplatin or carboplatin as well as (2) any chemotherapy. Finally, Cox proportional hazards regression was used to evaluate factors associated with 12-month relative hazard of death. Each model was adjusted for type of treatment, age at diagnosis, race/ethnicity, sex, insurance, Charlson comorbidity score, pneumonia/lung collapse at presentation, hospital ownership, [23] [24] [25] and the presence of a residency program in the treating facility. In separate models, we defined chemotherapy as etoposide plus cisplatin or carboplatin or as other chemotherapy. These models were not substantially different likely owing to the relatively small number of patients receiving other agents; therefore, we present the hazards models with "any" chemotherapy. All analyses were performed using the SUDAAN statistical software (Research Triangle Institute, Research Triangle Park, NC). All percentages are weighted to the SEER population from which the data were obtained using the inverse of the sampling fraction. The numbers are unweighted. All tests of statistical significance were assessed using the Wald-type F-statistics, with P<0.05 considered statistically significant.
RESULTS
In this population-based study of 931 patients with SCLC treated in the community and academic settings, 71.4% of the patients had a diagnosis of ES disease, whereas 28.6% presented with LS disease (Table 1) , which is similar to the distribution of SCLC cases in the United States as a whole. Unadjusted analyses identified no significant differences between LS and ES at presentation by age, race/ethnicity, sex, insurance 
Type of Treatments Received

Limited-Stage Disease
Of the patients with LS disease, 72.2% received chemoradiation as the initial treatment (Table 1) , with 2.1% indicating refusal of any type of treatment (n=13). Furthermore, only 59.5% of all patients with LS disease received etoposide with cisplatin or carboplatin and radiation. This decreased with age from 60% to 29% for those aged younger than 60 years and those older than 80 years, respectively (data not shown). Few patients (n=2) participated in clinical trials. Positron emission tomography (PET) scans were received by 43% of the patients with LS disease as part of their diagnosis and treatment planning.
After adjusting for patient and provider characteristics, we found that age at diagnosis and Charlson score were associated with receipt of etoposide with cisplatin or carboplatin plus radiation. Age, race/ethnicity, and pneumonia/lung collapse were associated with receiving any chemotherapy plus radiation (Table 2) . Specifically, we found that older patients (80+) were less likely to receive etoposide with cisplatin or carboplatin and thoracic radiation (odds ratio [OR], 0.15; 95% confidence interval [CI], 0.04-0.64) or any chemoradiation (OR, 0.06; 95% CI, 0.01-0.29). Patients with a Charlson score of 2+ were more likely to receive etoposide with cisplatin or carboplatin and radiation (OR, 2.81; 95% CI, 1.08-7.44). Patients of other/unknown race/ethnicity (OR, 0.29; 95% CI, 0.09-0.94) or with pneumonia/lung collapse (OR, 0.32; 95% CI, 0.15-0.72) were less likely to receive any chemotherapy and radiation. Thirty-five percent of patients (n=84) determined to be with LS disease received radiation to a nonprimary site as part of their initial therapy.
Extensive-Stage Disease
In the patients with ES disease at presentation, 30.2% received etoposide with cisplatin or carboplatin and 9.8% received "other" chemotherapy as the primary treatment with no radiation given (Table 1) . A further 18.8% received etoposide with cisplatin or carboplatin, and 6.3% received other chemotherapy with thoracic radiation. However, in the community and academic settings, 32.8% of the patients with ES disease received no chemotherapy or radiation, including 3.4% (n=33) who refused any type of treatment; 18% of those younger than 60 years and 74% of those older than 80 years received no treatment (data not shown). Less than 1% (n=9) of the patients were entered onto a clinical trial. A PET scan was part of the diagnosis and treatment planning for 26.4% of patients with an initial diagnosis of ES.
After adjusting for patient and provider characteristics, we found that only age was associated with receipt of etoposide plus cisplatin or carboplatin with no radiation, and age and the presence of an approved residency program at the treatment site was associated with receipt of any chemotherapy ( Table 2) . Patients aged 60 to 69 were more likely to receive etoposide plus cisplatin or carboplatin (OR, 2.14; 95% CI, 1.01-4.53). Patients aged 80 years or older were less likely to receive any chemotherapy (OR, 0.43; 95% CI, 0.20-0.94). Patients treated in hospitals with residency programs were more than twice as likely to receive chemotherapy compared to facilities without a residency program (OR, 2.01; 95% CI, 1.19-3.41).
12-month Mortality
Limited-Stage Disease
More than 43% of patients with LS disease in our study died within 12 months after diagnosis. After taking patient and hospital factors into account, we found that the type of treatment patients received was highly associated with 12-month relative hazard of death (Table 3 ). Compared to patients treated with chemoradiation, patients treated with radiation alone (hazard ratio [HR], 11.66; 95% CI, 5.09-26.67) and those receiving no treatment (HR,16.12; 95% CI, 7.89-32.95) experienced significantly poorer survival. Race/ethnicity was significantly associated with mortality. Overall, patients of black and other/unknown race/ethnicity experienced significantly lower relative hazard of death. Finally, patients treated in hospitals with an approved residency program experienced significantly higher relative mortality compared to facilities without training programs (HR, 1.84; 95% CI, 1.00-3.36).
Extensive-Stage Disease
Of the patients with ES disease treated in the community and academic settings, 72% were deceased 12 months after diagnosis. We found that treatment received was highly associated with 12-month relative hazard of death after adjusting for patient and hospital factors ( Table 3) . As with patients with a diagnosis of LS disease, those treated with radiation therapy only (HR, 3.60; 95% CI, 2.33-5.58) or received no treatment (HR, 5.45; 95% CI, 3.71-8.01) experienced significantly poorer survival compared to patients treated with any chemotherapy. Additionally, female patients had significantly lower relative hazard of death compared to males (HR, 0.67; 95% CI, 0.51-0.90). Finally, patients aged 70 to 79 (HR, 1.66; 95% CI, 1.12-2.45), 
DISCUSSION
Among all patients in this study, we found that approximately 29% presented with LS disease, whereas more than 71% had a diagnosis of ES disease; these study prevalences are similar to previous national estimates. 17 However, few studies have evaluated how these patients with SCLC are treated in community and academic settings.
We found that 59.5% of the patients with LS disease received chemoradiation containing the etoposide plus cisplatin or carboplatin doublet. For patients with ES disease, 30.2% received the cisplatin or carboplatin with etoposide regimen only as the initial treatment. Patients who received chemoradiation for LS or chemotherapy for ES experienced significantly lower mortality compared to those who received no therapy or radiation only. Elderly patients (80 or older at diagnosis), patients of other/ unknown race/ethnicity, and those with pneumonia/lung collapse were less likely to receive any chemotherapy plus radiation for LS disease. Patients treated in hospitals with residency programs were more likely to receive some chemotherapeutic agents for ES disease. These findings provide further insight into specific segments of the US population with SCLC who might benefit from efforts to improve receipt of standard therapy.
Overall, our findings indicate more extensive use of etoposide with cisplatin or carboplatin treatment for SCLC compared to studies of practice patterns in large hospitals and comprehensive cancer centers more than 2 decades ago. 17 In a study examining treatment patterns of patients in the 1988-1991 National Cancer Database, Fry et al 17 found that 33% of patients with American Joint Committee on Cancer stage I and stage II disease were treated with chemotherapy and radiation, whereas 39% of American Joint Committee on Cancer stage III and stage IV disease were treated with chemotherapy only. Although use of cisplatin or carboplatin with etoposide was still somewhat low during this period, use of this therapy is more widespread than previous studies report. Cisplatin or carboplatin and etoposide were given as a doublet to 71.5% of patients with LS disease and 49% of patients with ES disease in our study. We did not define the use of a platin/irinotecan combination as a US standard therapy in our study. During the study period, its use was not frequent. Only 23 patients (4.9%) with ES disease received irinotecan in a doublet with a platinum agent as part of their initial therapy. Although the use of irinotecan may have increased after 2007, definitive results of SWOG 0124 were not enough to change the standard of care at least in the United States. 22 This study allows us to identify those individuals who are at higher risk for not receiving recommended treatment. In a 2002 study of patients with SCLC treated in the British Columbia Cancer Agency, increasing age and comorbidity were both associated with lower use of combined chemoradiation. 26 Our study expands this treatment profile to evaluate treatment of patients with both LS and ES diseases in the US community and academic setting. Among the patients with LS disease, older patients were less likely to receive etoposide with cisplatin or carboplatin plus radiation for their disease, but those with a Charlson score of 2+ were more likely to receive this therapy. This may be a result of physicians providing a more complete recording of comorbidities for patients slated to receive more extensive therapy. In addition, radiation plus any chemotherapy was prescribed less frequently for patients 80 years or older, for other/unknown race/ethnicity, and for patients with pneumonia or lung collapse. We also found that 34% of the patients with LS disease received radiation to a nonprimary site as part of their initial therapy. Because of limitations on how the data were collected, we are unable to determine the exact radiation site. It is reasonable to speculate that most directed to the use of PCI after initial good control of their disease as per the established standard at the time of the study period. 7 For the patients with ES disease, however, only aged 80 years or older and the presence of a residency program where they were treated was associated with receiving any chemotherapy. These findings may be due to a combination of both patient and structural factors. Specifically, facilities with residency programs were also more likely to be large nonprofit facilities that typically have greater access to specialized resources for dedicated cancer care. Combined, these results indicate that a patient's risk profile and treating hospital characteristics may play a significant role in treatment planning for SCLC. Age as the only factor should not bias against receiving standard treatment when other variables are not increasing patient's risk. Future studies should evaluate the most effective mechanisms for, at a minimum, promoting receipt of standard treatment regimens while encouraging entry onto clinical trials.
Our study also adds to the growing body of literature examining factors that influence survival after SCLC diagnosis. Overall, our study confirms the poor prognosis of patients with SCLC in both community and academic settings, with survival rates that are comparable to other single institution and comprehensive cancer center settings. 17, [26] [27] [28] [29] We found that patients with LS disease treated in hospitals with residency programs experienced significantly higher mortality compared to those treated in a hospital with no approved residency program. Although underlying reasons are not clear, this finding might reflect characteristics of patients choosing specialized centers, where residents are likely present (i.e., lower functional status, more serious comorbidities, and perhaps more disseminated disease, even within limited stage).
Interestingly, this was not true for the patients with ES disease. However, this is not a randomized controlled trial, and the number of patients receiving other agents was relatively small. This may account for the lack of significant difference between the use of etoposide and cisplatin or carboplatin and other agents. Future studies might examine the impact of other factors such as patient's frailty that might be associated with survival in this population. Importantly, female sex, other and unknown race/ethnicity, and the absence of pneumonia/lung collapse are important factors for improved survival with ES disease. The specific factors leading to improved outcome in female patients need to be further investigated. Other/unknown race in our study included Asian Americans who historically have experienced better overall cancer survival relative to other racial/ethnic groups. 30 Improved outcome among patients without pneumonia/lung collapse may reflect a worse functional status and the inability of patients with pneumonia/lung collapse to receive standard therapy. Furthermore, we found that patients with Medicare coverage only and those aged 70 to 79 years had poorer survival. Medical care is costly, and patients with Medicare alone have significant out-of-pocket costs. Patients may choose not to receive all the care that is indicated owing to these costs. Interestingly, patients aged 70 to 79 years had a higher hazard of death, which may reflect differences in functional status compared to those younger than age 60 at diagnosis. Finally, those who did not receive treatment may have had such extensive disease that they were not candidates for therapy and, as a result, experienced higher mortality.
Our study provides information regarding the use of PET scans for diagnosis and treatment planning in the community and academic setting. Our finding that 43% of patients with LS disease and 26.4% of those with ES disease received a PET scan during the course of diagnosis and treatment is similar to other studies. In a 2010 study, Dinan et al 31 found that 35% to 53% of Medicare beneficiaries with incident lung cancer including all histologic classifications diagnosed between 1999 and 2006 received PET scans during their initial treatment. The implications for the use of PET scans in the initial staging strategy of LS disease are evident, as a more accurate determination of stage will affect prognosis and treatment. The appropriate integration and eventual value of this technology in ES SCLC remains to be well established.
Finally, an important concern is the very low enrollment on clinical trials in this population, with participation rates less than 1% among patients with both LS and ES diseases. Most efforts for improving survival for both LS and ES SCLC have focused on the use of novel therapeutic approaches in the clinical trial setting. The lack of significant progress in new systemic therapies for SCLC in the past 2 decades is reflective of the little progress in trials of therapy. 16 Identifying new therapies based on improved knowledge in the biology and molecular traits of SCLC will be crucial for improving the low survival rates. Furthermore, access to clinical trials can be a real concern for patients with newly diagnosed disease as they create their treatment plan with their oncologist. Only 53 first-line trials were open between January and December 2007 according to clinicaltrials. gov, which could create logistical challenges for enrollment such as long distances to enrolling facilities, travel, and other out-ofpocket costs.
Although our study provides insight into the practice patterns and outcomes of patients with LS and ES SCLC treated in the US population, we acknowledge several data-related limitations. First, the available data do not include measures of frailty, degree of weight loss, or performance status in the patients; and these may have influenced eligibility for or receipt of chemotherapy and/or radiation for SCLC. However, we adjusted for comorbidities in the Charlson score, which has been shown to be associated with 1-and 10-year mortality in hospitalized patients. Additionally, the data do not include information on the timing of pneumonia/lung collapse in patients. Our study data do not include information on all factors, including patients' or physicians' preferences in determining treatment planning that may influence treatment or outcomes. Future studies should prospectively plan to assess how these factors may affect treatment and outcome. Finally, as mentioned earlier, because of limitations in data collection, including information on the specific type of remission, we cannot provide definitive information regarding the use of PCI.
Acknowledging these limitations, our study is one of the first to evaluate treatment practices in a population-based sample of patients with SCLC in both community and academic settings and to assess survival outcomes. Specifically, we provide further insight into specific segments of the US population with SCLC who may benefit from efforts to improve receipt of standard therapy. As a result, future efforts to improve receipt of standard therapy might focus on patient-related factors, such as older age for LS disease, while examining hospital or system-level factors for improving receipt of standard therapy in ES disease. In conclusion, in our study of patients with SCLC treated in the community and academic setting, we found that still a somewhat large proportion of patients are not treated with a standard treatment regimen owing to a mixture of patient-and systemrelated factors. Efforts to promote and facilitate clinical trial enrollment to test novel therapies should be explored further.
